Document is current
Any future updates will be listed below
-
Authors
Gutfleisch, Matthias https://orcid.org/0000-0002-2001-5838
Heimes-Bussmann, Britta https://orcid.org/0000-0003-3898-1679
Aydin, Sökmen https://orcid.org/0000-0001-9791-7517
Petrovic, Ratko https://orcid.org/0009-0007-1905-1958
Loktyushin, Alexander https://orcid.org/0000-0001-6249-9124
Ohji, Masahito https://orcid.org/0000-0003-1565-8289
Takahashi, Kanji https://orcid.org/0000-0002-3537-5625
Okada, Annabelle A. https://orcid.org/0000-0002-8850-8962
Scholz, Paula https://orcid.org/0000-0002-1730-0566
Youssef, Hossam https://orcid.org/0009-0000-8876-8038
Bauer-Steinhusen, Ulrike https://orcid.org/0009-0002-4998-9035
Machewitz, Tobias https://orcid.org/0009-0005-6844-4243
Rothaus, Kai https://orcid.org/0000-0002-4288-8795
Lommatzsch, Albrecht https://orcid.org/0000-0001-9640-4103
-
Funding
Funding for this research was provided by:
Bayer Vital GmBH
- License Information
-
More Information
Article History
Received: 1 October 2024
Revised: 4 March 2025
Accepted: 24 March 2025
First Online: 10 April 2025
Declarations
:
: Both studies in this analysis were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines E6: Good Clinical Practice. The study protocols (and any amendments) were approved by the independent ethics committee or institutional review board (IRB) at each study site. Details of IRBs for ALTAIR are available at .
: Informed consent was obtained from all individual participants included in the studies.
: M. Gutfleisch received research support from Bayer and Novartis, is a consultant for Bayer, Novartis and Roche, and holds stock or shares in deepeye Medical GmbH.B. Heimes-Bussman received research support from Bayer and Novartis and is a consultant for Bayer, Novartis and Roche.A. Lommatzch received research support from Bayer, Novartis and Biogen, is a consultant for Bayer, Novartis, Roche, Zeiss, Apellis and Biogen, and holds shares in deepeye Medical GmbH.M. Ohji received financial support and honoraria from Alcon Japan, Novartis, Otsuka Pharmaceutical, Santen Pharmaceutical, Senju Pharmaceutical, financial support from HOYA, Chugai Pharmaceutical and AMO, honoraria from Bayer Yakuhin and Nikon, and was a consultant for Chugai Pharmaceutical.K. Takahashi has received grants and personal fees from Alcon Japan, Allergan Japan, Bayer Yakuhin, HOYA, Kowa, Kyowa Kirin, Nitto Medic, Novartis Pharma, Ono, Otsuka Pharmaceuticals, Santen Pharmaceutical, and Senju Pharmaceutical.A. Okada has received institution grants from Alcon Pharma KK, Bayer Yakuhin, Mitsubishi Tanabe Pharma, Pfizer KK and Santen Pharmaceutical, consulting fees from Allergan Japan, Apellis Pharmaceuticals, Astellas Pharma, Bayer Consumer Care AG, Bayer Yakuhin KK, Biocon Biologics, Chugai Pharmaceutical, Daiichi-Sankyo, and Kowa, and honoraria from Bayer Australia, Bayer Yakuhin KK, Chugai Pharmaceutical, Kowa, Mitsubishi Tanabe Pharma, Novartis Pharma KK, Otsuka Pharmaceutical, Santen Pharmaceutical and Senju Pharmaceutical. Dr Okada has also participated in Steering Committees or Advisory Boards with Bayer Consumer Care AG, Bayer Yakuhin and Chugai Pharmaceutical.K. Rothaus has received research support from Bayer and deepeye Medical GmbH.S. Aydin, R. Petrovic, and A. Loktyushin are employees of and may own shares in deepeye Medical GmbH.P. Scholz, H. Youssef, U. Bauer-Steinhausen and T. Machewitz are employees of and may own shares in Bayer.
